


Inflammatoir mammacarcinoom

Wat (weten we) nu?



-
- Conflict of interest: none.

Locally advanced breast cancer (LABC)

Non-inflammatory LABC (NI-LABC)




Inflammatory breast cancer (IBC)

T4a



T4b

T4c

T4d



“Inflammatie” ten gevolge van lymfoedeem




Quiz



1% 5% 8%



23% 57% 68%




17% 30% 39%

iKNL



Incidentie



17.869 patiënten
~NI-LABC: 14.388 [4.0%]
~IBC: 3.481 [1.1%]

Leeftijd
~NI-LABC: 69,1 jaar
~IBC: 61,6 jaar

Graad 3
~NI-LABC: 53,8%
~IBC: 69,8%


ER+
~NI-LABC: 79,4%
~IBC: 58,4%


HER2+
~NI-LABC: 18,5%
~IBC: 34,0%


Triple negatief
~NI-LABC: 12,8%
~IBC: 23,3%


N+
~NI-LABC: 69,7%
~IBC: 77,8%

M+
~NI-LABC: 34,1%
~IBC: 39,7%












survival



— NI-LABC
- - - IBC





— Surgery
- - - Trimodality therapy

Discussie



Registratiefenomeen? Awareness?



↓ ER+

↑ HER2

↑ Triple negatief

↑ gr III

↑ N₊

↑ M₊



Toename survival

17.2% - 30.0% - 38.9%



Multimodale therapie

23.7% - 56.0% - 68.6%


Conclusie



Agressieve kenmerken



Slechte prognose



Behandeling op maat



Noodzaak voor targeted therapie



NI-LABC

